| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435346000 | Fused or hybrid cell, per se | 26 |
| 20090275126 | ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR AND USES THEREOF - Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy. | 11-05-2009 |
| 20100086997 | TrkB Agonists for Treating Autoimmune Disorders - Tyrosine receptor kinase (TrkB) agonists are provided for reducing leukocyte invasion of the central nervous system in autoimmune diseases such as multiple sclerosis. TrkB agonists include naturally-occurring agonists, such as NT4 and BDNF, as well as agonists such as agonist antibodies. | 04-08-2010 |
| 20100093080 | Tooth Regeneration Method - Disclosed is a novel method for formation of a tooth by producing a chimera embryoid body using an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal and then cultivating the chimera embryoid body on a three-dimensional matrix. A tooth is formed by co-cultivating an undifferentiated cell and a dental mesenchymal cell derived from a mammal of the same species as that of the target mammal in the presence of an induction factor to produce a chimera embryoid body, and then cultivating the chimera embryoid body on a three-dimensional matrix. The cultivation of the chimera embryoid body on the three-dimensional matrix is performed either by cultivating the chimera embryoid body in a serum culture medium without the induction factor for three days; or cultivating the chimera embryoid body in a culture medium supplemented with the induction factor for two days, and further cultivating the chimera embryoid body in a serum culture medium without the induction factor for three days. The undifferentiated cell is at least one cell selected from all stem cells including an ES cell. The mammal is one selected from all mammals. The induction factor is activin, bone morphogenic protein 4, insulin growth factor 1, fibroblast growth factor 2, or transforming growth factor β1. | 04-15-2010 |
| 20100197009 | Antibody or Fragment Thereof Recognizing AvitagTM and Uses Thereof - The application relates to antibodies which recognize the AviTag™ peptide of sequence MSGLNDIFEAQKIEWHE (SEQ ID No. 1) and to fragments thereof which recognize SEQ ID No. 1, wherein said antibodies or said fragments thereof recognize polypeptides containing SEQ ID No. 1 at their NH2 terminus and polypeptides containing SEQ ID No. 1 at their COOH terminus. The application further relates to a method for sorting target cells presenting on their surface a surface marker from a mixed cell population comprising the steps of: a) incubating said mixed cell population with a tagged adapter which binds to said surface marker of said target cells, wherein said adapter is bound to an antibody which recognizes said tag, and wherein said antibody is immobilized on a solid support. b) collecting said target cells. | 08-05-2010 |
| 20100227395 | CANINE TUMOR CELL AND ALLOGENEIC DENDRITIC CELL FUSED VACCINE AND METHOD FOR PREPARING THE SAME - The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body. | 09-09-2010 |
| 20100279401 | T Cell Hybridomas And Related Compositions And Methods For Assaying And Modulating T Cell Receptor-Mediated Immune Responses - The present invention provides T cell hybridomas and related compositions and assay systems for investigative, diagnostic, and therapeutic use in modulating T cell receptor (TCR)-mediated immune response. The T cell hybridomas of the invention are typically constructed by fusing a naïve or early central memory T cell isolated from a mammalian subject with an immortalizing fusion partner (e.g. mammalian lymphoid tumor cell) to yield clonal T cell hybrids. The resulting T cell hybridomas exhibit antigen (Ag)-specific proliferation responsiveness over a background level of proliferation of the hybridomas. These hybridomas are useful for screening, identifying, and characterizing T cell immune modulatory agents, for example recombinant T cell receptor ligands (RTLs) and other agents that can modulate TCR-mediated T cell immune responses. Ag-specific proliferative response profiles exhibited by the T cell hybridomas of the invention show sufficient amplitude, sensitivity and fidelity to distinguish and/or quantify the presence and/or activity of a test RTL or other test modulatory agent in screening and sensitivity assays employing the hybridomas. These and other aspects of the invention yield powerful tools and methods for developing and characterizing novel RTLs and other immune modulatory agents for use in treating immune disorders, including a wide range of autoimmune diseases, in mammals. | 11-04-2010 |
| 20110020928 | IMMUNOVECTORS WHICH CAN BE USED FOR THE INTRACELLULAR AND INTRANUCLEAR TRANSPORT - A method of transferring a biologically active principle of interest into a cell by coupling an antibody or a fragment of an antibody, which recognizes an epitope contained in a nucleic acid, with the biologically active principle, to form a coupled biologically active principle; and incubating the coupled biologically active principle, which is transferred through the cell membrane and into the cell, with the cell. | 01-27-2011 |
| 20110039330 | ANIMAL CELL CULTURE MEDIA COMPRISING NON ANIMAL OR PLANT DERIVED NUTRIENTS - The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production. | 02-17-2011 |
| 20110039331 | TAG PEPTIDE AND USE THEREOF - The present invention provides a tag peptide comprising an amino acid sequence represented by the following formula (I): | 02-17-2011 |
| 20110065184 | HUMAN HOST CELL FOR PRODUCING RECOMBINANT PROTEINS WITH HIGH QUALITY AND QUANTITY - The present invention relates to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, by using genetic engineering techniques. The human host cell with stable characteristics well preserved may be efficiently used to produce heterologous desired recombinant protein-based pharmaceuticals. | 03-17-2011 |
| 20110275149 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
| 20110294208 | METHOD AND DEVICE FOR CELL SELECTION AND COLLECTION IN AN ISOLATED CULTURING ENVIRONMENT - An apparatus for collecting or culturing cells or cell colonies has a common substrate and a plurality of cell carriers releasably connected to the common substrate. The carriers are arranged in the form of an array. The invention employs microcups as the cell carriers. The substrate is preferably free of barriers between the microcups, and in some embodiments the microcups have porous walls. Methods of using the apparatus are also described. | 12-01-2011 |
| 20120083032 | EMBRYONIC STEM CELL LINE AND METHOD FOR PREPARING THE SAME - An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types. | 04-05-2012 |
| 20120264208 | MATERIALS AND METHODS FOR ENHANCED IRON UPTAKE IN CELL CULTURE - A serum-free, synthetic tissue culture media is described which is completely defined chemically. The media do not require any supplementation with serum to support growth of cells. The media and methods described herein can also be used for growing all types of mammalian cell lines in culture without addition of transferrin protein. The media include a basal medium and an activator of iron uptake. The media also include a defined cell culture media that includes an iron-containing compound, which is capable of supporting the growth of mammalian cells in culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells. | 10-18-2012 |
| 20120295344 | Stem Cell Fusion Model of Carcinogenesis - Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the discovery and evaluation of new therapeutic targets to inhibit metastasis and other markers of carcinogenesis. | 11-22-2012 |
| 20130065300 | DRY POWDER CELLS AND CELL CULTURE REAGENTS AND METHODS OF PRODUCTION THEREOF - The present invention relates generally to nutritive medium, medium supplement, media subgroup and buffer formulations. Specifically, powdered nutritive medium, supplement, subgroup formulations, cell culture media comprising all of the necessary nutritive factors for in vitro cell cultivation, buffer formulations that produce particular ionic and pH conditions upon reconstitution with a solvent are provided. Particularly, methods of production of these media, supplement, subgroup, buffer formulations and kits, and methods for the cultivation of prokaryotic and eukaryotic cells using these dry powdered nutritive media, supplement, subgroup and buffer formulations are provided. Methods of producing sterile, powdered media or supplement (e.g., powdered FBS, powdered transferrin, powdered insulin, powdered organ extracts, powdered growth factors), media subgroup and buffer formulations by gamma irradiation are provided. Methods for producing dry cell powders, comprising spray-drying a cell suspension, and cells, media, media supplement, media subgroup and buffer powders produced by these methods are provided. | 03-14-2013 |
| 20130102073 | METHODS FOR MAKING AND USING REPROGRAMMED HUMAN SOMATIC CELL NUCLEI AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS - Activated human embryos produced by therapeutic cloning can give rise to human totipotent and pluripotent stem cells from which autologous cells for transplantation therapy are derived. The present invention provides methods for producing activated human embryos that can be used to generate totipotent and pluripotent stem cells from which autologous cells and tissues suitable for transplantation can be derived. The ability to create autologous human embryos represents a critical step towards generating immune-compatible stem cells that can be used to overcome the problem of immune rejection in regenerative medicine. The activated human embryos produced by the present invention also provide model systems for identifying and analyzing the molecular mechanisms of epigenetic imprinting and the genetic regulation of embryogenesis and development. | 04-25-2013 |
| 20130130373 | Kit Comprising Serum Replacement and Labile Factors - The present disclosure relates, in general to a kit comprising a serum replacement and one or more labile factors, such as growth factors, packaged separately in the kit. It is contemplated that the kit provides advantages to improve cell growth in culture compared to cells cultured not using the kit described herein. | 05-23-2013 |
| 20130157356 | METHODS & COMPOSITIONS FOR IMPROVING PROTEIN PRODUCTION - The invention relates to compositions, and uses thereof, which are beneficial for eukaryotic cells in culture, and methods for their use in promoting cell growth, viability and recombinant protein expression. The methods disclosed in the present application are useful, for example, for improving cell viability and in accelerating the rate of cell growth of cells grown in culture. In one aspect, the supplements of the invention are useful for improving or enhancing the yield of the recombinant proteins from the cell cultures. | 06-20-2013 |
| 20130196429 | Protein-Free Gamete and Embryo Handling and culture Media Products - This invention discloses a substantially protein-free cell culture solution for assisted reproductive technologies and methods of use thereof. | 08-01-2013 |
| 20130230917 | Method of Forming Dendritic Cells from Embryonic Stem Cells - This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers. | 09-05-2013 |
| 20140154800 | EMBRYONIC STEM CELL LINE AND METHOD FOR PREPARING THE SAME - An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types. | 06-05-2014 |
| 20140273203 | Host Cells with Artificial Endosymbionts - The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria. | 09-18-2014 |
| 20140329312 | METHOD FOR PRODUCING HUMAN MONOCLONAL IMMUNOGLOBULIN G ANTIBODIES - The present invention a method for producing a human immunoglobulin G (IgG) antibody using a prime-boost regime in a Bone Marrow Liver Thymic (BLT) mouse. | 11-06-2014 |
| 20150024485 | PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION - This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR). | 01-22-2015 |
| 20160100570 | ULTRA-HIGH DENSITY CELL BANKING METHODS - Provided are methods for the creation of ultra-high density cryopreserved cell banks. In certain embodiments, these methods employ altered perfusion culture techniques that allow for production of ultra-high density cell cultures that can be cryopreserved at unexpectedly high cell densities without the need for any cell concentration steps, while retaining excellent cell viability and quality. | 04-14-2016 |
